Back to search results

Improving Medication Adherence for Heart Failure Patients

This study is looking for people with heart failure (HF) who have trouble taking their medications as prescribed. The goal is to find better ways to help patients and their care partners (like a spouse or family member) work together to take medications correctly. You would either receive the FamLit intervention, which uses easy-to-understand materials and coaching from nurses, or an Attention Control intervention where you discuss general health and use an electronic pillbox. Researchers want to see if these strategies improve how well people take their medications and reduce hospitalizations over 12 months. This study aims to improve your quality of life by helping you manage your heart failure medications.

Study design
This interventional study plans to enroll 328 participants and compares two behavioral interventions: FamLit and Attention Control.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months to measure medication adherence.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05548413

Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies

Recruiting
NAAges 18+Interventional
Jia-Rong Wu
~328 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:FamLitAttention Control

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Medication adherence
Measured over 12 months
+1 more outcome measured

Conditions

Medication Adherence
Heart Failure

Explore related trials

Heart Failure

NCT05548413

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Jia-Rong Wu

    Lexington, Kentuckystudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jia-Rong Wu · PRINCIPAL_INVESTIGATOR · University of Kentucky

Who to contact

Jia-Rong Wu, PhD
[email protected]
8593234712
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

confirmed diagnosis of heart failure (HF), either systolic or diastolic HF
ave suboptimal medication adherence
have a care partner (CP) (either spouse, daughter/son, partner, other relative, friend) who is identified by the patient as the person most involved in HF care
willingness to have a CP be involved in their medication taking
have undergone evaluation of HF and prescribed stable doses of HF medications for at least 3 months
live in a setting where the patient is responsible for their ow medication administration
willing to use the SimpleMed+ (i.e., an electronic pillbox to measure objective medication adherence)
availability by phone
unpaid family member, friend, partner, or other relation who is involved in the patients' care at least 3 times a week, designated by the patient
willing to receive interventions with the patient together
18 years of age or older

Exclusion

cognitive impairment as indicated by having difficulties to understand and give informed consent
a recent hospitalization within 3 months of study enrollment
co-existing end-stage renal disease or terminal illness such as advanced malignancy, or any other condition with less than 1-year life expectancy
psychotic illness
current alcohol dependence or other substance abuse
inability to speak English or other communication barrier
currently or have received any similar self-care intervention recently in the past year
cognitive impairment as indicated by having difficulties to understand and give informed consent
coexisting terminal illness
non-English speaking or any other communication barrier

What this trial measures

  • Medication adherence12 months

    Percentage of prescribed doses taken (PDT%) as determined by the electronic SimpleMed+ pillbox. SimpleMed+ will record the date and time that the lid of each compartment is opened and closed. Those data will be used to calculate objective medication adherence: percent prescribed doses taken (PDT%) = (# of doses taken during monitoring period)/(# of prescribed doses during monitoring period) x 100.PDT% ranges from 0-100%.

  • Self-reported medication adherence.12 months

    Adherence will be surveyed the Basel Assessment of Adherence Scale (BAAS), a copyrighted, self-reported scale. The BAAS includes 5 yes-no items and one visual analogue scale (VAS). If participants indicate they have missed a dose (a "yes" response) to any of 5 dichotomous items and \<80% on the VAS, they are classified as suboptimally medication adherent.